Results 51 to 60 of about 586,353 (306)

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin   +11 more
wiley   +1 more source

Hepatitis B discrimination: global responses requiring global data

open access: yesBMC Public Health
Over 250 million individuals live with chronic hepatitis B (CHB) infection worldwide. A significant proportion of these people often face discrimination defined as the unjust, unfair, or prejudicial treatment of a person on the grounds of their hepatitis
Catherine Freeland   +14 more
doaj   +1 more source

Hepatitis A, B, and C [PDF]

open access: yesSexually Transmitted Infections, 2006
Hepatitis A, B, and C cause acute infection of the liver that may manifest as an acute icteric illness or be detected incidentally as raised transaminase levels.1 Most cases are diagnosed only in retrospect on serological screening. Hepatitis B and C can persist as chronic infections (>6 months). ### Hepatitis A Hepatitis A virus (HAV) is transmitted
R, Gilson, M G, Brook
openaire   +2 more sources

Neurovascular Contacts in the Pathophysiology of Neuralgic Amyotrophy: An Observational Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neuralgic amyotrophy (NA) is a prevalent, monophasic, multifocal immune‐mediated neuropathy. A distinctive characteristic of the disease is the occurrence of nerve or fascicle constrictions and torsions (NA‐associated focal nerve lesions, NAFL). The pathophysiology underlying this phenomenon remains to be fully elucidated.
Johannes Fabian Holle   +4 more
wiley   +1 more source

Human Pegivirus Encephalitis With Brain Detection and Response to Sofosbuvir Ledipasvir

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Human pegivirus (HPgV‐1) has been associated with severe encephalomyelitis in immunocompromised patients. Its neurological spectrum remains poorly defined. We report a slowly progressive encephalitis in a person living with well‐controlled HIV, characterized by white matter abnormalities and inflammatory cerebrospinal fluid (CSF). HPgV RNA was
Antoine Moulignier   +3 more
wiley   +1 more source

Long‐Term Neurologic Exam Findings in People Diagnosed and Treated During Acute HIV Infection

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Evaluate clinical and laboratory correlates of abnormal neurologic exam findings after acute HIV infection (AHI). Methods Participants from the RV254/SEARCH 010 cohort in Bangkok underwent standardized neurologic examinations at Weeks 0 (AHI), 12, 96, and 288 following antiretroviral therapy (ART).
Kathryn B. Holroyd   +118 more
wiley   +1 more source

Cracking the Code: Which Ocular Symptoms Predict Dry Eye Signs? Insights From a Large International Sicca Registry

open access: yesArthritis Care &Research, EarlyView.
Objective The study aimed to identify symptom‐based predictors of dry eye disease (DED) signs in the Sjögren's International Collaborative Clinical Alliance (SICCA) cohort. Methods We performed a retrospective analysis examining 16 ocular symptoms (most graded 0–4) and artificial tear (AT) use (graded 0–3) as predictors of DED signs (abnormal ocular ...
Pragnya R. Donthineni   +7 more
wiley   +1 more source

Table 1-1. National notification and print criteria for hepatitis A, hepatitis B, and hepatitis C [PDF]

open access: yes
Table 1-1 describes the national notification criteria for hepatitis A, hepatitis B, and hepatitis C case statuses, based on the current Council of State and Territorial Epidemiologists (CSTE) Position Statements. This table supports general surveillance

core  

Home - About - Disclaimer - Privacy